Target-responsive subcellular catabolism analysis for early-stage antibody-drug conjugates screening and assessment.
10.1016/j.apsb.2021.05.024
- Author:
Hua SANG
1
;
Jiali LIU
1
;
Fang ZHOU
1
;
Xiaofang ZHANG
1
;
Jingwei ZHANG
1
;
Yazhong LIU
1
;
Guangji WANG
1
;
Hui YE
1
Author Information
1. Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Publication Type:Journal Article
- Keywords:
ADC;
Biosimilarity;
Screening;
T-DM1;
Target-responsive subcellular catabolism (TARSC);
Therapeutic efficacy
- From:
Acta Pharmaceutica Sinica B
2021;11(12):4020-4031
- CountryChina
- Language:English
-
Abstract:
Events including antibody‒antigen affinity, internalization, trafficking and lysosomal proteolysis combinatorially determine the efficiency of antibody-drug conjugate (ADC) catabolism and hence the toxicity. Nevertheless, an approach that conveniently identifies proteins requisite for payload release and the ensuing toxicity for mechanistic studies and quality assessment is lacking. Considering the plethora of ADC candidates under development, we developed a target-responsive subcellular catabolism (TARSC) approach that examines ADC catabolism and probes changes in response to targeted interferences of proteins of interest. We firstly applied TARSC to study the commercial T-DM1 and the biosimilar. We recorded unequivocal catabolic behaviors regardless of the absence and presence of the targeted interferences. Their negligible differences in TARSC profiles agreed with their undifferentiated anti-tumoral efficacy according to further
